Rationale for routine use of IORT for early breast cancer and data for specific indications

Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany
Rationale for routine use of IORT for early breast cancer and data for specific indications ( Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany )
29 Jun 2023

Chest wall perforator flaps in breast cancer surgery: An overview

Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India
Chest wall perforator flaps in breast cancer surgery: An overview ( Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India )
22 Jun 2023

Advancing breast cancer treatment in Uganda by improving molecular testing

Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda
Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )
8 Jun 2023

Somatic mutation profile of breast cancer in Uganda

Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA
Somatic mutation profile of breast cancer in Uganda ( Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA )
8 Jun 2023

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
6 Jun 2023

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2023

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )
6 Jun 2023

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )
5 Jun 2023

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
5 Jun 2023

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Prof Dennis Slamon - UCLA, Los Angeles, USA
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )
3 Jun 2023

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )
3 Jun 2023

Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer

Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India
Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer ( Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India )
25 May 2023